Skip to main content
Qualitek Labs Limited logo

Qualitek Labs Limited — Investor Relations & Filings

Ticker · 544091 ISIN · INE0Q1R01012 LEI · 894500JDSLOLB9FZAS39 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 6 across all filing types
Latest filing 2026-05-21 Investor Presentation
Country IN India
Listing BSE.NS 544091

About Qualitek Labs Limited

https://www.qualiteklab.com

Qualitek Labs Limited provides comprehensive testing, inspection, and certification services across diverse sectors including automotive, defense, aerospace, and environmental management. The company operates advanced laboratories equipped for chemical, metallurgical, and mechanical analysis, ensuring material integrity and regulatory compliance. Key service offerings include metallurgical testing, failure analysis, environmental monitoring, and microbiological assessments. By leveraging sophisticated analytical instrumentation and adhering to international quality standards like ISO/IEC 17025, the firm supports manufacturers and government agencies in verifying product safety and performance. Its technical expertise extends to mineral testing and water quality analysis, providing critical data for industrial and research applications.

Recent filings

Filing Released Lang Actions
Investor presentation for H2 & FY26 of Qualitek Labs Limited
Investor Presentation Classification · 92% confidence The document is a formal filing under SEBI LODR Regulation 30 with the subject “Investor Presentation H2 & FY 2025-26” and encloses a detailed slide deck containing financial results, strategy, and operational highlights. This matches the definition of an Investor Presentation (IP), rather than an earnings release (ER) or report announcement (RPA).
2026-05-21 English
The enclosed Management Discussion and Analysis (MD&A) provides an overview of the company''s consolidated and standalone financial and key operational highlights, and the future outlook ....
Management Reports Classification · 95% confidence The document is a letter to the Bombay Stock Exchange submitting the company’s Management Discussion & Analysis (MD&A) for H2 FY25-26. It contains substantive analysis of half-year and full-year financial performance, business trends, outlook, and operational highlights. This matches our definition for Management Reports (MDA), which are management’s detailed explanation of financial results, business trends, and outlook. It is a standalone MD&A report, not just an announcement, and includes actual financial data and forward guidance, so it should be classified as MDA.
2026-05-20 English
Audited Standalone and Consolidated Financial Results as on 31.03.2026
Audit Report / Information Classification · 87% confidence The document is a Board Meeting outcome notice under SEBI Listing Regulations (Reg 30 & 33) that encloses the Independent Auditor’s Report and the full audited standalone and consolidated financial results for the half‐year and year ended March 31, 2026. It contains the complete auditor’s opinion and full financial tables, but it is not a comprehensive annual report (10-K) and exceeds a mere announcement of publication. This aligns with the definition of a standalone Audit Report/Information (AR). FY 2026
2026-05-20 English
In terms of Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of Qualitek Labs Limited ....
Audit Report / Information Classification · 89% confidence The document is a regulatory filing under SEBI LODR Regulation 33 that delivers the audited standalone and consolidated financial results along with the Independent Auditor’s Report. It contains the full audit opinion, basis for opinion, management and auditor responsibilities, and the detailed financial results table. This is not merely an announcement or a proxy statement; it is the actual audit report and audited financial results. Therefore it best fits the “Audit Report / Information (AR)” category. FY 2026
2026-05-20 English
Qualitek Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2026 ,inter alia, to consider and approve Audited Financial Results (Standalone ....
Regulatory Filings Classification · 90% confidence The document is an intimation under SEBI Listing Regulations about rescheduling of a Board Meeting. It is a compliance announcement to the stock exchange, not an actual financial report or management change announcement. This fits best under the general regulatory filings category (RNS).
2026-05-15 English
Qualitek Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 of ....
Regulatory Filings Classification · 93% confidence The document is a notice under SEBI (Listing Obligations) Regulation 29 to the stock exchange informing of an upcoming Board meeting date for approving audited results. It does not contain actual financial statements or decisions, nor does it announce board changes. It is a general regulatory announcement/fallback disclosure. Therefore it should be classified as a Regulatory Filing (RNS).
2026-05-12 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.